CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
CIViC Variants/Amplification

Amplification

CIViC ID: 306 · Gene: ERBB2

Variant Summary

Also known as
OVEREXPRESSION
HGVS
—
Variant Type(s)
transcript_amplification
Evidence Items
65

Evidence Level Distribution

Level A: 4Level B: 43Level C: 5Level D: 13

Evidence Items

Showing CIViC evidence rows where gene = ERBB2 and variant = Amplification.

LevelTypeDirectionSignificanceDiseaseDrugsRating
DPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerA662
DPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPalbociclib,Trastuzumab2
DPredictiveSupportsSensitivity/ResponseBreast CancerMTOR Kinase Inhibitor PP2422
BPredictiveSupportsResistanceColorectal CancerPanitumumab,Cetuximab2
CPredictiveSupportsSensitivity/ResponseScrotum Paget's DiseaseTrastuzumab2
BPredictiveSupportsSensitivity/ResponseBiliary Tract CancerPertuzumab,Trastuzumab2
BPredictiveSupportsSensitivity/ResponseSalivary Gland CarcinomaPertuzumab,Trastuzumab2
BPredictiveSupportsSensitivity/ResponsePancreatic CancerPertuzumab,Trastuzumab2
BPredictiveDoes Not SupportSensitivity/ResponseUterine CancerTrastuzumab,Pertuzumab2
DPredictiveSupportsSensitivity/ResponseUterine Corpus Endometrial CarcinomaAfatinib2
BPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerLapatinib,Afatinib,Trastuzumab2
DPredictiveSupportsSensitivity/ResponsePancreatic AdenocarcinomaAfatinib2
CPredictiveSupportsResistanceLung AdenocarcinomaGefitinib,Erlotinib1
BPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,Capecitabine,Oxaliplatin1
BPredictiveSupportsSensitivity/ResponseChildhood EpendymomaLapatinib1
Page 2 of 2
Previous